Earnings

Bristol Myers Squibb Announces Topline Results From Unit RayzeBio's Planned Interim Analysis Of ACTION-1 Trial; RYZ101 Study Met Primary Endpoint With Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival By Blinded Independent Central Review, And Safety Results Consistent With Known Safety Profile

Oct 12, 2026 · 07:03 AM ET· updated 57m ago

Bristol Myers Squibb (NYSE:BMY) today announced positive topline results from the planned interim analysis of the ACTION-1 trial (NCT05477576) conducted by RayzeBio, Inc., a Bristol Myers Squibb company. The study met

Why It Matters

Bristol Myers Squibb's medicine RYZ101 worked better than expected in a big trial. When a company's new medicine succeeds, it can mean more patients helped and future sales growth.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

BMY61.25

+2.13 (+3.60%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.